NAD+Cellular CoenzymeSafety Rating 7/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 500mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Ascension PeptidesBest $/mgCOA ✓ · 3POut of stock | $29.00 | $0.0580 | Apr 16, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3POut of stock | $62.06 | $0.0621 | May 19, 2026 | Buy → |
| Petratide ScienceCOA ✓ · 3P | $64.95 | $0.0650 | May 14, 2026 | Buy → |
| Petratide ScienceCOA ✓ · 3P | $34.95 | $0.0699 | May 14, 2026 | Buy → |
| Ascension PeptidesCOA ✓ · 3P | $75.00 | $0.0750 | Apr 16, 2026 | Buy → |
Overview
About NAD+
Mechanism of action
Coenzyme in redox reactions; activates sirtuins (SIRT1-7) and PARP; critical for mitochondrial function, DNA repair, and cellular energy (ATP) production.
Safety profile
IV: flushing, nausea, headache, chest tightness (infusion-rate dependent). SC: injection site discomfort. Generally safe. · IV widely used in clinics; flushing/nausea common but transient; endogenous molecule; no serious AEs reported
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops NAD+ below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Chemotherapy — some evidence that high NAD+ may reduce efficacy of certain chemotherapeutics. Avoid during active cancer treatment without oncology guidance.
IV infusion rate — rapid infusion causes chest tightness, nausea, anxiety. Slow drip (2-4 hrs) is safer.
PARP inhibitors (olaparib, rucaparib) — NAD+ precursors may counteract therapeutic effect.
Related pages
More on NAD+
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- NAD+ declines ~50% from age 40 to 60 in human whole blood, contributing to impaired sirtuin activity, reduced DNA repair capacity, and mitochondrial dysfunction — the mechanistic basis for NAD+ supplementation research.
- IV infusion of NAD+ rapidly raises plasma and whole-blood NAD+ metabolome, providing superior bioavailability vs oral precursors for acute repletion.